NVAX · Novavax Inc
$8.05
-0.09 (-1.11%)
At close · Aug 14
Market Cap
$1.33B
Shares
164.95M
Novavax Inc Earnings Call Transcripts
Every quarterly earnings call for Novavax Inc (NVAX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲310.7%
$734.58M
−$168.61M
'22 Q3
22-11-08
▲60.8%
$357.40M
−$182.25M
'22 Q4
23-02-28
▼88.5%
$80.95M
−$293.90M
'23 Q1
23-05-09
▲128.3%
$424.43M
$58.01M
'23 Q2
23-08-08
▼74.5%
$186.99M
−$130.78M
'23 Q3
23-11-09
▼18.5%
$291.34M
−$178.39M
'23 Q4
24-02-28
▲15.9%
$93.86M
−$147.55M
'24 Q1
24-05-10
▼2.1%
$415.48M
$162.38M
'24 Q2
24-08-08
▼54.8%
$84.51M
−$121.30M
'24 Q3
24-11-12
▼69.7%
$88.31M
−$81.03M
'24 Q4
25-02-27
▲610.3%
$666.65M
$518.65M
'25 Q1
25-05-08
▼42.4%
$239.24M
$106.51M
'25 Q2
25-08-06
▼16.6%
$70.44M
−$202.38M
'25 Q3
25-11-06
▲66.6%
$147.14M
$17.53M
'25 Q4
26-02-26
▼79.1%
$139.51M
−$9.49M
'26 Q1
26-05-06
LATEST
▼76.3%
$56.70M
−$53.39M
'26 Q2
26-08-06
Earnings call
FY26 · Q2
2026-08-06
Novavax Inc Q2 FY2026 Earnings Call
Revenue
$56.70M
▼ 76.3% YoY Diluted EPS
$-0.32
▼ 151.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-04
Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Novavax Inc Q1 FY2026 Earnings Call
Confident tone
Matrix-M partnering strategy
R&D pipeline and preclinical assets
Sanofi partnership and Nuvaxovid
Revenue
$139.51M
▼ 79.1% YoY Diluted EPS
$-0.06
▼ 102% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Novavax Inc Q4 FY2025 Earnings Call
Confident tone
Partnership strategy and business development
Oncology and platform expansion
R&D pipeline and innovation
Revenue
$147.14M*
▲ 66.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Novavax Inc Q3 FY2025 Earnings Call
Positive tone
Sanofi partnership and transition activities
Matrix-M adjuvant and technology platform
Strategic transformation to partnership/R&D model
Revenue
$70.44M
▼ 16.6% YoY Diluted EPS
$-1.25
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Novavax Inc Q2 FY2025 Earnings Call
Confident tone
Sanofi Partnership and Nuvaxovid BLA Approval
Strategic Priorities and Growth Platform
Oncology and Adjuvant Expansion
Revenue
$239.24M
▼ 42.4% YoY Diluted EPS
$0.62
▼ 37.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Novavax Inc Q1 FY2025 Earnings Call
Positive tone
New partnerships and collaborations
Sanofi partnership optimization
BLA approval and FDA process
Revenue
$666.65M
▲ 610.3% YoY Diluted EPS
$2.93
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Novavax Inc Q4 FY2024 Earnings Call
Positive tone
Sanofi Partnership
Early-Stage Pipeline and Partnerships
CIC and Standalone Flu Phase 3
Revenue
$88.31M*
▼ 69.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Novavax Inc Q3 FY2024 Earnings Call
Positive tone
Late-stage pipeline (CIC and flu)
Financial guidance and revenue
COVID-19 commercial season and pricing
Revenue
$84.51M
▼ 54.8% YoY Diluted EPS
$-0.76
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Novavax Inc Q2 FY2024 Earnings Call
Positive tone
Sanofi partnership and value drivers
COVID-19 commercial readiness and BLA
Technology platform and business development
Revenue
$415.48M
▼ 2.1% YoY Diluted EPS
$0.99
▲ 70.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-10
Novavax Inc Q1 FY2024 Earnings Call
Confident tone
Sanofi Co-Development/Co-Commercialization Agreement
Regulatory Timing and Strain Selection
Matrix-M Adjuvant Platform Value
Revenue
$93.86M
▲ 15.9% YoY Diluted EPS
$-1.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Novavax Inc Q4 FY2023 Earnings Call
Positive tone
APA Contract Revenue and Deliveries
Czech Manufacturing Plant Divestiture
COVID-Flu Combination Vaccine Pipeline
Revenue
$291.34M*
▼ 18.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Novavax Inc Q3 FY2023 Earnings Call
Revenue
$186.99M
▼ 74.5% YoY Diluted EPS
$-1.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Novavax Inc Q2 FY2023 Earnings Call
Revenue
$424.43M
▲ 128.3% YoY Diluted EPS
$0.58
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Novavax Inc Q1 FY2023 Earnings Call
Revenue
$80.95M
▼ 88.5% YoY Diluted EPS
$-3.41
▼ 233.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Novavax Inc Q4 FY2022 Earnings Call
Revenue
$357.40M*
▲ 60.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Novavax Inc Q3 FY2022 Earnings Call
Revenue
$734.58M
▲ 310.7% YoY Diluted EPS
$-2.15
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Novavax Inc Q2 FY2022 Earnings Call
Revenue
$185.93M
▼ 37.6% YoY Diluted EPS
$-6.53
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Novavax Inc Q1 FY2022 Earnings Call
Revenue
$703.97M
▲ 57.4% YoY Diluted EPS
$2.56
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Novavax Inc Q4 FY2021 Earnings Call
Revenue
$222.20M*
▼ 20.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-05
Novavax Inc Q3 FY2021 Earnings Call
Revenue
$178.84M
▲ 13.9% YoY Diluted EPS
$-4.31
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-06
Novavax Inc Q2 FY2021 Earnings Call
Revenue
$298.02M
▲ 738.6% YoY Diluted EPS
$-4.75
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-11
Novavax Inc Q1 FY2021 Earnings Call
Revenue
$447.23M
▲ 13143.4% YoY Diluted EPS
$-3.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-02
Novavax Inc Q4 FY2020 Earnings Call
Revenue
$279.66M*
▲ 3072.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-10
Novavax Inc Q3 FY2020 Earnings Call
Revenue
$157.02M
▲ 6163.4% YoY Diluted EPS
$-3.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-11
Novavax Inc Q2 FY2020 Earnings Call
Revenue
$35.54M
▲ 958.6% YoY Diluted EPS
$-0.30
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-12
Novavax Inc Q1 FY2020 Earnings Call
Revenue
$3.38M
▼ 15.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-12
Novavax Inc Q4 FY2019 Earnings Call
Revenue
$8.82M
▲ 43.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls
Key facts
CIK
1000694
CUSIP
670002401
13F (30d)
276 filings
251 filers
Visit website
Investor relations